Serial Number
86357775
Owner
TRUVERIS, INC.Attorney
Edmund J. Ferdinand IIIFirst Use Date
Mar 21, 2014
Filing Date
Aug 5, 2014
LAMP Trademark
Serial Number: 86357775 • Registration: 4707895
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Edmund J. Ferdinand, III Meister Seelig & Fein PLLC
125 Park Avenue
7th Floor
New York, NY 10017
United States
Trademark Details
Filing Date
August 5, 2014
Registration Date
March 24, 2015
First Use Anywhere
March 21, 2014
First Use in Commerce
March 21, 2014
Published for Opposition
January 6, 2015
Cancellation Date
October 10, 2025
Goods & Services
Platform as a service (PAAS) featuring computer software platforms for use in tracking and monitoring pharmaceutical drug sales and dispensations, for use in tracking, analyzing and determining pharmaceutical drug market share, for use in tracking, analyzing and determining pharmaceutical drug co-pay distribution, for use in tracking, monitoring, analyzing and determining patient-adherence or patient-abandonment to pharmaceutical drug administration, for use in tracking, monitoring and analyzing pharmaceutical drug pricing, for use in tracking and monitoring pharmaceutical drug loss-of-exclusivity readiness, for use in evaluating, comparing and analyzing the different market performance attributes of similar pharmaceutical drugs, and for use in monitoring, tracking and reporting on the market performance of various pharmaceutical drugs throughout their respective lifecycles; Software as a service (SAAS) services featuring software for use in tracking and monitoring pharmaceutical drug sales and dispensations, for use in tracking, analyzing and determining pharmaceutical drug market share, for use in tracking, analyzing and determining pharmaceutical drug co-pay distribution, for use in tracking, monitoring, analyzing and determining patient-adherence or patient-abandonment to pharmaceutical drug administration, for use in tracking, monitoring and analyzing pharmaceutical drug pricing, for use in tracking and monitoring pharmaceutical drug loss-of-exclusivity readiness, for use in evaluating, comparing and analyzing the different market performance attributes of similar pharmaceutical drugs, and for use in monitoring, tracking and reporting on the market performance of various pharmaceutical drugs throughout their respective
